The Philadelphia, PA-based biotech develops
engineered T cell therapies, chimeric antoantibody receptor (CAAR) T
cells, for B cell-mediated autoimmune disorders. The company says its
proprietary CABA platform
is applicable across 24 of these diseases thus far. Lead candidate is
DSG3-CAART for the potential treatment of a rare skin blistering
disorder called pemphigus vulgaris. A Phase 1 study should commence in 2020.
2019 Financials (6 mo.): Operating Expenses: $7.8M (+644%); Net Loss: ($12.2M) (-999%); Cash Burn: ($6.1M) (-261%).
https://seekingalpha.com/news/3506176-cabaletta-bio-deck-ipo
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.